Scholay

学术搜索 · AI 审稿 · LaTeX 协作

Victoria M. Rimkunas

机构：Xilio Therapeutics (United States) · ORCID：0000-0003-4263-2009

发表论文 197 篇 · 总被引 1777 次 · h-index 17

代表论文

  • Figure 1 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results (2026)
  • Supplementary Table S1 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results (2026)
  • Supplementary Table S3 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results (2026)
  • Figure 2 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results (2026)
  • Supplementary Table S2 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results (2026)
  • Supplementary Table S4 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results (2026)